Relay Advisors

Fourth-Quarter Surge in Deals Lends (Cautious) Hope for 2010

 

  • The National Venture Capital Association recently reported that biotech investments declined 19 percent in 2009 compared to 2008.
  • The industry saw a surprise fourth-quarter surge in deal-making:  75 deals at a total value of $15 billion.

  • Among big pharmaceutical firms, Novartis was busy in the fourth quarter, signing seven deals worth $2.4 billion. GlaxoSmithKline PLC was busier with nine deals of a value of $2.8 billion.

Takeaway: Biotech investment is expected to pick up in 2010, especially with players like Merck & Co. Inc being mostly absent in 2009.


Source: Jennifer Boggs at BioWorld Today

 



Relay Advisors is a corporate finance firm specialized in strategic asset optimization and divestiture.

Relay gives its network of Advisors access to its platform, knowledge base, deal flow and the opportunity to earn consulting and referral fees. Apply to our Advisory Board, or sign up for our newsletter.

 

Comments

No comments have been posted yet.
Post a comment
  1. You must be logged in to post a comment.
  2. Must be less than 400 characters. Allowed HTML tags: <a>, <b>, <i>, <u>.